drugset / Trial / NCT04778956
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Phase 3
Recruiting
218 enrolled
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University · collabFirst People's Hospital of Foshan · collabNanfang Hospital, Southern Medical University · collabTenth Affiliated Hospital, Sun Yat-sen University · collabZhongshan People's Hospital, Guangdong, China · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that PD-1 treatment added to salvage surgery could further decrease the rate of disease progression and improve the survival outcome of patients with resectable locally recurrent nasopharyngeal carcinoma compared with those treated with salvage surgery alone.
Timeline
- Start
- 2021-03-03
- Primary completion
- 2025-03-03
- Completion
- 2033-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |